Immix Biopharma, Inc.
IMMX
$1.99
-$0.42-17.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.65% | 58.80% | 21.99% | 63.97% | 94.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.23% | -7.23% | 63.47% | 26.39% | 121.76% |
| Operating Income | 16.23% | 7.23% | -63.47% | -26.39% | -121.76% |
| Income Before Tax | 14.83% | 6.72% | -64.59% | -22.38% | -113.49% |
| Income Tax Expenses | 11.36% | 33.33% | 63.24% | 63.49% | 69.23% |
| Earnings from Continuing Operations | 14.79% | 6.66% | -64.58% | -22.45% | -113.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -100.00% | -- | -41.36% | 291.85% |
| Net Income | 13.62% | 5.45% | -67.01% | -22.84% | -112.08% |
| EBIT | 16.23% | 7.23% | -63.47% | -26.39% | -121.76% |
| EBITDA | 16.87% | 7.56% | -63.40% | -26.30% | -121.69% |
| EPS Basic | 31.86% | 30.34% | -5.47% | 35.83% | -25.78% |
| Normalized Basic EPS | 31.27% | 29.85% | -6.39% | 35.72% | -25.27% |
| EPS Diluted | 31.86% | 30.34% | -5.47% | 35.83% | -25.78% |
| Normalized Diluted EPS | 31.27% | 29.85% | -6.39% | 35.72% | -25.27% |
| Average Basic Shares Outstanding | 26.72% | 35.73% | 58.38% | 91.40% | 68.65% |
| Average Diluted Shares Outstanding | 26.72% | 35.73% | 58.38% | 91.40% | 68.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |